|

entinostat Clinical Trials

4 actively recruiting trials across 1 location

▲ +1 trial since July 2026

Also known as: HDAC inhibitor, HDAC inhibitor SNDX-275, MS 27-275, MS 275, MS-275 +4 more

Pipeline

Phase 2: 2Phase 1/2: 2

Top Sponsors

  • Zhejiang Cancer Hospital1
  • Tianjin Medical University Cancer Institute and Hospital1
  • National Cancer Institute (NCI)1
  • Hebei Medical University Fourth Hospital1

Indications

  • Cancer4
  • Breast Cancer3
  • Refractory Pancreatic Carcinoma1
  • Locally Advanced Pancreatic Carcinoma1
  • Stage II Pancreatic Cancer AJCC v81

Other3 trials

A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
Phase 2
Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
Phase 2
Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
Phase 1/2

New Haven, Connecticut1 trial

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Yale University

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.